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The nose is not the only relevant MRSA
screening site
We agree with Struelens et al. [1] that the most important
methicillin-resistant Staphylococcus aureus (MRSA) screening
site is the nose and not the throat as was claimed by Bignar-
di et al. [2]. However, in contrast to Struelens et al., we sub-
mit that the nose is not the only relevant screening site but
should be considered alongside the throat, perineum and, if
necessary, other (clinical) sites.
More generally, we call for a standardization of screening
guidelines. There is an increasing trend among the general
public to compare hospitals and, as a consequence, pressure
mounts on hospitals to disclose epidemiological data (i.e.
data concerning MRSA). However, regardless of the suitabil-
ity of these data for the comparison of hygiene standards
among hospitals, its meaningfulness is dubious in the absence
of uniform screening criteria. Each hospital chooses its own
target population; some hospitals screen only the nose,
whereas others screen the nose and perineum or the nose
and throat.
In our institution, we have chosen to screen the nose,
perineum and throat. Additional swabs can be taken from
wounds. Sometimes urine and sputa are also screened for
MRSA. Upon admission we routinely screen patients coming
from other healthcare facilities, patients aged > 70 years,
patients known to have been MRSA positive in the past, and
patients who are farmers or veterinary surgeons. We also
screen patients who have shared a room with an MRSA-posi-
tive patient and patients awaiting an implant.
The samples are cultured in a homemade liquid medium.
This medium consists of trehalose (5 g), mannitol (5 g), NaCl
(20 g), phenol red (0.7%) (3 g), aztreonam (75 mg from
50 mg/mL), polymyxin (16 mg from 1.6 mg/mL), ciproﬂoxacin
(4 mg from 2 mg/mL) with nutrient broth (25 g) per litre.
Since some of the MRSA strains in our institution are cipro-
ﬂoxacin sensitive, we additionally use a traditional sheep
blood agar as well as, for perineum samples, a sheep blood
agar with colimycin and nalidixic acid. Note that, in order to
obtain optimal sensitivity for MRSA screening, the enrich-
ment broth does not contain more than 2.5% NaCl, in
accordance with Bruins et al. [3] and conﬁrmed by in-house
research.
From 1 January 2008 to 31 December 2008, 2060 patients
were screened among a total of 14 594 patients admitted to
our hospital. A total of 180 of these patients was MRSA posi-
tive. Forty of these patients were thought to have a clinically
signiﬁcant infection. Only 140 samples were found to be posi-
tive by pure screening, 78.4% within 48 h after admission.
We decontaminated at least 47.8% of the patients. The
other half left our hospital before we could end the decon-
tamination procedure (including three consecutive negative
screening samples).
Table 1 indicates that nose swaps provide both the larg-
est number of overall MRSA isolates as well as the largest
number of MRSA isolates found on a single site. This sug-
gests that the nose is the most important MRSA screening
site. This ﬁnding contrasts with that of Bignardi et al. [2],
although there were a considerable number of positive
throat swabs, which means that screening of the throat is
indeed useful [4,5]. Moreover, the prevalence of isolates in
the throat, nose and perineum suggests that there is an
added value to the screening of all three sites in the
search for MRSA.
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Isolation of Moellerella wisconsensis from
blood culture from a patient with acute
cholecystitis
Moellerella wisconsensis is a Gram-negative bacillus of the fam-
ily Enterobacteriaceae previously called Enteric Group 46 [1].
The name M. wisconsensis was proposed in 1984 by Hickman-
Brenner et al. for strains from patients with diarrhoea,
because the majority of the examined strains had been iso-
lated from clinical specimens in the state of Wisconsin, USA.
Isolates of M. wisconsensis have been recovered from animals,
water and human food. Its pathogenicity in humans has not
been established, although it has been isolated from clinical
specimens other than stools, such as gall bladder tissue [2,3]
or bile [4]. We report a case of isolation of this organism
from blood culture.
An 80-year-old man with a history of type 1 insulin-depen-
dent diabetes and hypertension was admitted to the hospital.
He had been complaining of abdominal pain in the right
upper quadrant and jaundice for several weeks, in the
absence of fever, vomiting or diarrhoea. Physical examination
revealed a temperature of 38.1C, and pallor and tenderness
in the right upper quadrant, with positive Murphy’s sign. Lab-
oratory ﬁndings included a glucose level of 187 mg/mL and a
bilirubin level of 2.8 mg/mL. Leukocytosis of 14 000/mm3
with 87% polymorphonuclear leukocytes was observed.
Abdominal sonography showed a distended gall bladder with
biliary sludge, suggestive of acute acalculous cholecystitis.
Two blood cultures were performed, immediately after the
fever spikes at admission, in BACTEC plus Aerobic/F and
Plus Anaerobic/F bottles (BACTEC 9240; Becton Dickinson,
Sparks, MD, USA). No other specimens were collected for
microbiological study. Empirical treatment with intravenous
piperacillin–tazobactam (4 g every 8 h) was started.
The BACTEC system found all vials to be positive after
24 h of incubation. A Gram smear from blood of the four
bottles showed Gram-negative bacilli and Gram-positive
cocci in chains. Subculture was performed on ordinary media
and also on differential media for growth of Gram-positive
and Gram-negative organisms (phenylethanol blood agar and
and MacConkey agar, respectively). After 24 h of incubation
at 37C, a mixed culture of Gram-negative bacilli and Gram-
positive cocci was found. Both were submitted to routine
identiﬁcation, using the GN and GP Vitek system cards (bio-
Me´rieuxe´, Marcy l’Etoile, France), and identifed as M. wiscons-
ensis and Enterococcus faecium, respectively. On MacConkey
agar, the colonies of M. wisconsensis were similar to colonies
of Escherichia coli. Because of the lack of published criteria
for the identiﬁcation of this microorganism, identiﬁcation
was repeated with the GN Vitek card; the API ID 32 E iden-
tiﬁcation strip (bioMerieux) was also used, and motility and
resistance to colistin were tested, leading to the identiﬁca-
tion of the bacterium as M. wisconsensis with 99% probability.
Species identiﬁcation was conﬁrmed by 16S rRNA gene
sequencing (1215 bp), using a previously reported method
[5]. The sequence determined showed 99% identity with the
M. wisconsensis type strain DSM 5676T (GenBank accession
number AM040754.1). With respect to the DSM 5676T
numbering, two changes were detected, at positions 148
(GﬁC) and 222 (GﬁA). This 16S rDNA gene sequence was
deposited in GenBank under accession number GQ451444.
Antibiotic susceptibility was tested with the AST-N057 Vi-
tek system card, and showed that the isolate was susceptible
to amikacin, ampicillin, amoxycillin–clavulanate, aztreonam,
cefepime, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cip-
roﬂoxacin, fosfomycin, gentamicin, imipenem, piperacillin–ta-
zobactam, tobramycin and tygecycline, and resistant to co-
trimoxazole. Open cholecystectomy was performed at 24 h
of admission, and the patient received postoperative paren-
teral intravenous piperacillin–tazobactam (4 g every 8 h) for
7 days. Complete remission of the symptoms was achieved;
the patient was discharged from the hospital 1 week after
admission, and then received oral amoxycillin–clavulanate
(875/125 mg every 8 h) for 5 days.
The majority of M. wisconsensis isolates from human clini-
cal samples have been recovered from stool specimens [6,7];
however, they have also been recovered from other speci-
mens, such as bronchial aspirates [8], infected gall bladder
[2,3], biliary samples [4] and, in one case, peritoneal exudate
[9]. To our knowledge, this is the ﬁrst case documenting the
isolation of M. wisconsensis from blood taken from a patient
with acute cholelithiasis. The organism was correctly identi-
ﬁed using two commercial identiﬁcation systems, the GN Vitek
card and the API ID 32 E identiﬁcation strip (bioMerieux),
and it was considered to be clinically signiﬁcant. Previous
studies have correlated the presence of this microorganism
with cholecystitis episodes, but in all of them the isolates
were recovered from the gall bladder [2–4]. The results of
the susceptibility test were in agreement with those
reported previously [4,8,9], except that the isolate of
the present study was susceptible to fosfomycin. We believe
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